Ventripoint Diagnostics to Settle Debt Through Share Issuance
November 6, 2025 — Leads & Copy —Ventripoint Diagnostics Ltd. (TSXV:VPT) has announced an agreement to settle an aggregate of $542,591.50 of debt owed to certain arm’s length creditors of the Corporation.
The settlement will be facilitated by issuing an aggregate of 5,425,915 common shares of the Corporation at a price of $0.10 per share, totaling $542,591.50. The common shares issued are subject to a hold period of four months and one day. The company decided to use shares to settle the debt in order to preserve cash for business development.
The issuance of the shares is subject to approval by the TSX Venture Exchange.
Ventripoint has become an industry leader in applying artificial intelligence to echocardiography. Ventripoint’s VMS products are powered by its proprietary knowledge-based reconstruction technology, the result of a decade of development, and provide accurate volumetric cardiac measurements equivalent to MRI. This affordable, gold-standard alternative allows cardiologists greater confidence in managing their patients.
VMS+ is versatile and can be used with all ultrasound systems from any vendor supported by regulatory market approvals in the U.S., Europe, and Canada.
Hugh MacNaught hmacnaught@ventripoint.com 604-671-4201
Source: Ventripoint Diagnostics Ltd.
Share this story:
